Resistance to KRAS(G12C) Inhibitors in Non-Small Cell Lung Cancer

KRAS mutations are one of the most prevalent oncogenic alterations in cancer. Until recently, drug development targeting KRAS did not convey clinical benefits to patients. Specific KRAS(G12C) inhibitors, such as sotorasib and adagrasib, have been designed to bind to the protein’s mutant structure an...

Descripción completa

Detalles Bibliográficos
Autores principales: Blaquier, Juan Bautista, Cardona, Andrés Felipe, Recondo, Gonzalo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739760/
https://www.ncbi.nlm.nih.gov/pubmed/35004309
http://dx.doi.org/10.3389/fonc.2021.787585

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739760/
https://www.ncbi.nlm.nih.gov/pubmed/35004309
http://dx.doi.org/10.3389/fonc.2021.787585

Ejemplares similares